Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HHSN275201800001I | Other Grant/Funding Number | NICHD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the incidence of Zika virus (ZIKV) infection among pregnant women with and without Human Immunodeficiency Virus (HIV) infection and to determine the risk of adverse maternal and child outcomes associated with ZIKV/HIV co-infection across clinical sites in the continental United States (U.S.), Puerto Rico (P.R.) and Brazil.
This is a two-phase prospective international cohort study of pregnant women and their infants from those pregnancies whose goals are to compare the incidence of ZIKV infection among pregnant women with and without HIV infection and to determine the risk of adverse maternal and child outcomes associated with ZIKV/HIV co-infection across clinical sites in the continental U.S., P.R. and Brazil.
Phase I will enroll pregnant women/infant pairs who are: (1) infected with HIV only; (2) infected with ZIKV only; (3) infected with HIV and ZIKV; and (4) not infected with HIV or ZIKV. Phase I will assess the feasibility of enrolling a total of 200 pregnant women/infant pairs within a year, with a target of 150 HIV-infected women, 50 HIV-uninfected women from the continental U.S. sites only, and a minimum of 20 who are co-infected with HIV and ZIKV by the end of pregnancy.
Should the feasibility of Phase I prove successful, Phase II will commence by enrolling up to 1,800 additional pregnant women/infant pairs to the 4 groups described above. The comparison group of HIV-uninfected pregnant women/infant pairs from P.R and Brazil (ZIKV-infected and uninfected) will be obtained from data collected in the concurrent International Prospective Observational Cohort Study of Zika in Infants and Pregnancy (ZIP study).
All HIV-infected and uninfected study participants will be tested for ZIKV. Enrolled women will be followed throughout their pregnancy and up to six weeks postpartum. Infants born to enrolled women will be followed for a full year after birth. Thereafter, the infants born to women at continental U.S. and P.R. sites also implementing the Surveillance Monitoring for Antiretroviral Therapy (ART) Toxicities (SMARTT) study may be followed up yearly until adulthood through SMARTT depending on the availability of funds.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Women with HIV only | Pregnant women with HIV infection only | ||
| Women with ZIKV only | Pregnant women with ZIKV infection only | ||
| Women with HIV and ZIKV | Pregnant women with HIV and ZIKV infection | ||
| Women without HIV or ZIKV | Pregnant women without HIV or ZIKV infection | ||
| Infants of women with HIV only | Infants of women with HIV infection during pregnancy | ||
| Infants of women with ZIKV only | Infants of women with ZIKV infection during pregnancy | ||
| Infants of women with HIV and ZIKV | Infants of women with HIV and ZIKV infection during pregnancy | ||
| Infants of women without HIV or ZIKV |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Enrollment (150 HIV-infected and 50 HIV-uninfected Pregnant Women Within One Year, With a Minimum of 20 of These Women Having HIV/ZIKV Co-infection by Their End of Pregnancy). | This outcome measured feasibility of enrolling 150 pregnant women living with HIV and 50 pregnant women without HIV, with a minimum of 20 of these women having HIV/ZIKV co-infection by their end of pregnancy | At the time of delivery of all those enrolled up to 1 year after the first enrollment |
| Viral Suppression (in HIV-infected Women With ZIKV Co-infection Compared to Those Without ZIKV Co-infection During Pregnancy) at the Time of Delivery. | This outcome intended to measure HIV suppression at the time of delivery among women living with HIV with and without ZIKV infection during pregnancy. Note there were no women with ZIKV infection in pregnancy. Viral suppression was defined at different thresholds (<40 copies/mL, <400 copies/mL, <1000 copies/mL). | Maternal viral load at delivery |
| Incidence of ZIKV Infection (Among Pregnant Women With HIV Infection Compared to Those Without HIV Infection). | Cumulative incidence of ZIKV infection during pregnancy (among pregnant women with HIV infection compared to those without HIV infection). | Maternal baseline to delivery |
| Incidence of Adverse Pregnancy Outcomes (in Women Co-infected With HIV and ZIKV, Women Infected With Either HIV or ZIKV Alone, and Doubly Uninfected Women). | Adverse pregnancy outcomes included miscarriage, stillbirth and preterm delivery. Note there were no women with ZIKV infection in pregnancy. Miscarriage was defined as fetal demise at <20 weeks of gestation. Stillbirth was defined as fetal demise at ≥20 weeks of gestation. Preterm delivery was defined as delivery at <37 weeks of gestation. | At time of delivery |
| Incidence of Vertical Transmission of HIV and/or ZIKV (in Women Co-infected With HIV and ZIKV and Women Infected With Either HIV or ZIKV Alone). |
Not provided
Not provided
Inclusion Criteria:
Maternal
Has met one of the following three ZIKV-exposure risk categories:
Has resided in for at least three months or traveled within the last three months to a country or United States (U.S.) territory with active, cautionary, or previously active or cautionary ZIKV transmission based on the list found at http://www.cdc.gov/zika/geo/active-countries.html; or
Sexual partner has resided in or traveled within the last six months to a country or U.S. territory with active, cautionary, or previously active or cautionary ZIKV transmissions, or was diagnosed with ZIKV within the previous six months; or
Household member has been diagnosed with ZIKV infection or has traveled since the woman's last menstrual period (LMP) to a country or U.S. territory with active, cautionary, or previously active or cautionary ZIKV transmission.
Infant
Exclusion Criteria:
Maternal:
Infant:
•Enrolled in other clinical research (including other ZIKV research) requiring blood collection, which in combination with HIV ZIP evaluations, would exceed three mL per kg in an eight week period and/or blood collection would be required more frequently than two times per week.
Not provided
Not provided
Not provided
Maternal: HIV infected or uninfected (the latter in the continental U.S only) pregnant women, ages 15 years and older, residing in a geographic area accessible to a research site in Brazil, Puerto Rico or the continental U.S., meet the ZIKV infection risk criteria and are less than 18 weeks GA or any GA if presenting with acute ZIKV-like symptoms and have confirmed ZIKV infection by positive ZIKV RNA detection at the Screening visit.
Infant: All infants born to women while enrolled in this study if the parent(s)/legal guardian(s) consents for the infant's participation. Infants may be in one of the following groups: a) HIV infected only; b) ZIKV infected only; c) HIV and ZIKV infected; or d) HIV and ZIKV uninfected
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marisa M. Mussi-Pinhata, MD | University of Sao Paolo, Riberao Preto Medical School, Department of Pediatrics | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Miami Pediatric/Prenatal HIV/AIDS | Miami | Florida | 33146 | United States | ||
| Bronx-Lebanon Hospital Center NICHD CRS |
De-identified participant data will be entered into the National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub (N-DASH) system.
Data from the ZIP study, conducted in Zika-endemic areas, may be merged with HIV ZIP. In most cases, ZIP will have the exact same infant assessments as HIV ZIP.
No later than one year after the date of acceptance for publication of the main findings from the final dataset.
A Memorandum of Understanding (MOU) about the extent and nature of the sharing as well as a data use agreement will be executed for all collaborations. The MOU will include an understanding of the control of the use of the data, publication rights and authorship rights, as well as address the human participant's confidentiality issues
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Women With HIV Only | Pregnant women with HIV infection only |
| FG001 | Women With ZIKV Only | Pregnant women with ZIKV infection only |
| FG002 | Women With HIV and ZIKV | Pregnant women with HIV and ZIKV infection |
| FG003 | Women Without HIV or ZIKV | Pregnant women without HIV or ZIKV infection |
| FG004 | Infants of Women With HIV Only | Infants of women with HIV infection during pregnancy |
| FG005 | Infants of Women With ZIKV Only | Infants of women with ZIKV infection during pregnancy |
| FG006 | Infants of Women With HIV and ZIKV | Infants of women with HIV and ZIKV infection during pregnancy |
| FG007 | Infants of Women Without HIV or ZIKV | Infants of women without HIV or ZIKV infection during pregnancy |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
At baseline (start of study) pregnant women were enrolled. Baseline characteristics of these women enrolled during pregnancy are therefore presented in this table. Live-born infants of these women were subsequently followed for one year if consent was obtained.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Women With HIV Only | Pregnant women with HIV infection only |
| BG001 | Women With ZIKV Only | Pregnant women with ZIKV infection only |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Enrollment (150 HIV-infected and 50 HIV-uninfected Pregnant Women Within One Year, With a Minimum of 20 of These Women Having HIV/ZIKV Co-infection by Their End of Pregnancy). | This outcome measured feasibility of enrolling 150 pregnant women living with HIV and 50 pregnant women without HIV, with a minimum of 20 of these women having HIV/ZIKV co-infection by their end of pregnancy | While the protocol was successful at enrolling at least 150 women living with HIV, it did not achieve its aim of enrolling 50 women without HIV and there were no ZIKV infections observed during the study period. Total enrollment into the expected arms is presented. | Posted | Count of Participants | Participants | At the time of delivery of all those enrolled up to 1 year after the first enrollment |
|
Through study completion, up to 1 year of follow-up of live-born infant.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Women With HIV Only | Pregnant women with HIV only | 1 |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Marisa Mussi-Pinhata | Department of Pediatrics Ribeirão Preto Medical School | 55-16-3602-2807 | mmmpinha@fmrp.usp.br |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 20, 2017 | Sep 30, 2021 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form: Maternal Informed Consent | Mar 20, 2017 | Sep 30, 2021 | ICF_001.pdf |
| ICF | No | No | Yes | Informed Consent Form: Infant Informed Consent | Mar 20, 2017 | Sep 30, 2021 | ICF_002.pdf |
Not provided
| ID | Term |
|---|---|
| D000071243 | Zika Virus Infection |
| ID | Term |
|---|---|
| D000096724 | Mosquito-Borne Diseases |
| D000079426 | Vector Borne Diseases |
| D007239 | Infections |
| D001102 | Arbovirus Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Maternal blood, maternal urine, cord blood, and placenta tissue. Infant blood and infant urine.
Infants of women without HIV or ZIKV infection during pregnancy |
Cumulative incidence of confirmed HIV infection among enrolled infants. Note there were no women with ZIKV infection in pregnancy so therefore no risk of transmission of ZIKV to any infants. |
| Infant birth to 12 months |
| Incidence of Congenital Malformations (Among Offspring of Women Co-infected With HIV and ZIKV, Women Infected With Either HIV or ZIKV Alone, and Doubly Uninfected Women). | Cumulative incidence of congenital malformations. Note there were no women with ZIKV infection in pregnancy. Observed major congenital malformations included: anhydramnios, cerebral ventriculomegaly, clubfoot (unresolved), Down syndrome, hydrops, hypospadias, patient ductus arteriosus, polydactyly (left foot), Potter syndrome, short stature, syndactyly (left foot, 1st and 2nd toes). Observed minor congenital malformations included: clubfoot (resolved), cryptorchidism (bilateral), dislocated hip, heart defect (patent foramen ovale), heart murmur (unresolved), hemangioma, hip dysplasia, hydrocele, inguinal hernia, head circumference -3 ≤ z-score <-2, persistent ductus arteriosus (resolved), plagiocephaly, restrictive ductus arteriosus, renal pyelectasis, sacral dimple, small perimembranous ventricular septal defect, stenosis of nasolacrimal duct, umbilical hernia. | Infant birth, 3 months |
| Incidence of Other Adverse Outcomes Among Offspring of Women Co-infected With HIV and ZIKV, Women Infected With Either HIV or ZIKV Alone. | Other adverse outcomes included microcephaly, neonatal dealth, central nervous system (CNS) malformation, hydrops, and ocular abnormalities. Note there were no women with ZIKV infection in pregnancy. Microcephaly was defined as head circumference less than a z-score of -3 at birth or 3 month visit. Neonatal death was defined as death within 28 days of life. Observed CNS malformations included: cerebral ventriculomegaly. Ocular abnormalities included both structural and functional ophthalmologic abnormalities. | Infant birth to 12 months |
| Weight Among Children With or Without in Utero Exposure to HIV and/or ZIKV | Weight as a measure of growth. Note there were no women with ZIKV infection in pregnancy. | Infant Birth, 3 months, 6 months, 12 months |
| Length and Head Circumference Among Children With and Without in Utero Exposure to HIV and/or ZIKV | Length and head circumference as measures of growth. Note there were no women with ZIKV infection in pregnancy. | Infant Birth, 3 months, 6 months, 12 months |
| Audiologic Function Among Children With or Without in Utero Exposure to HIV and/or ZIKV | Audiologic function as assessed by OAE test reported. Note there were no women with ZIKV infection in pregnancy. | Within one month of infant birth, 3 months, 6 months, 12 months |
| Ophthalmologic Structure and Function Among Children With or Without in Utero Exposure to HIV and/or ZIKV | Ocular abnormalities included both structural and functional ophthalmologic abnormalities. Note there were no women with ZIKV infection in pregnancy. | Within one month of infant birth, 12 months; |
| Neurodevelopment Among Children With or Without in Utero Exposure to HIV and/or ZIKV | Infant neurodevelopment was assessed by either the Bayley III or Ages and Stages Questionnaires- 3rd Edition. Combined results reported. Note there were no women with ZIKV infection in pregnancy. | Infant 3 months, 6 months, 12 months |
| The Bronx |
| New York |
| 10457 |
| United States |
| Baylor College of Medicine; Texas Children's Hospital | Houston | Texas | 77030 | United States |
| Baylor College of Medicine | Houston | Texas | 77030 | United States |
| SOM Federal University Minas Gerais Brazil NICHD CRS | Belo Horizonte | Minas Gerais | 30.130-100 | Brazil |
| Hospital Federal dos Servidores do Estado NICHD CRS | Rio de Janeiro | 20221-903 | Brazil |
| Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS | Rio de Janeiro | 21941-612 | Brazil |
| Hosp. Geral De Nova Igaucu Brazil NICHD CRS | Rio de Janeiro | 26030 | Brazil |
| University of Sao Paulo at Riberaio Preto Brazil | São Paulo | 14049-900 | Brazil |
| University of Puerto Rico Pediatrics HIV/AIDS Research Program | San Juan | 00936-5067 | Puerto Rico |
| San Juan City Hosp. PR NICHD CRS | San Juan | 00936 | Puerto Rico |
| BG002 | Women With HIV and ZIKV | Pregnant women with HIV and ZIKV infection |
| BG003 | Women Without HIV or ZIKV | Pregnant women without HIV or ZIKV infection |
| BG004 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Gestational age at enrollment | Median | Inter-Quartile Range | weeks |
|
| OG001 | Women With ZIKV Only | Pregnant women ZIKV infection only |
| OG002 | Women With HIV and ZIKV | Pregnant women with HIV and ZIKV infection |
| OG003 | Women Without HIV or ZIKV | Pregnant women without HIV or ZIKV infection |
|
|
| Primary | Viral Suppression (in HIV-infected Women With ZIKV Co-infection Compared to Those Without ZIKV Co-infection During Pregnancy) at the Time of Delivery. | This outcome intended to measure HIV suppression at the time of delivery among women living with HIV with and without ZIKV infection during pregnancy. Note there were no women with ZIKV infection in pregnancy. Viral suppression was defined at different thresholds (<40 copies/mL, <400 copies/mL, <1000 copies/mL). | All women with HIV enrolled in HIV ZIP during pregnancy | Posted | Count of Participants | Participants | Maternal viral load at delivery |
|
|
|
| Primary | Incidence of ZIKV Infection (Among Pregnant Women With HIV Infection Compared to Those Without HIV Infection). | Cumulative incidence of ZIKV infection during pregnancy (among pregnant women with HIV infection compared to those without HIV infection). | Women with HIV and women without HIV enrolled in HIV ZIP during pregnancy | Posted | Count of Participants | Participants | Maternal baseline to delivery |
|
|
|
| Primary | Incidence of Adverse Pregnancy Outcomes (in Women Co-infected With HIV and ZIKV, Women Infected With Either HIV or ZIKV Alone, and Doubly Uninfected Women). | Adverse pregnancy outcomes included miscarriage, stillbirth and preterm delivery. Note there were no women with ZIKV infection in pregnancy. Miscarriage was defined as fetal demise at <20 weeks of gestation. Stillbirth was defined as fetal demise at ≥20 weeks of gestation. Preterm delivery was defined as delivery at <37 weeks of gestation. | Women enrolled in HIV ZIP during pregnancy Miscarriage was defined as fetal demise <20 weeks of gestation. Stillbirth was defined as fetal demise ≥20 weeks of gestation. Preterm delivery was defined as delivery at <37 weeks of gestation. | Posted | Count of Participants | Participants | At time of delivery |
|
|
|
| Primary | Incidence of Vertical Transmission of HIV and/or ZIKV (in Women Co-infected With HIV and ZIKV and Women Infected With Either HIV or ZIKV Alone). | Cumulative incidence of confirmed HIV infection among enrolled infants. Note there were no women with ZIKV infection in pregnancy so therefore no risk of transmission of ZIKV to any infants. | Infants enrolled in HIV ZIP who were born to women with HIV or ZIKV infection in pregnancy. | Posted | Count of Participants | Participants | Infant birth to 12 months |
|
|
|
| Primary | Incidence of Congenital Malformations (Among Offspring of Women Co-infected With HIV and ZIKV, Women Infected With Either HIV or ZIKV Alone, and Doubly Uninfected Women). | Cumulative incidence of congenital malformations. Note there were no women with ZIKV infection in pregnancy. Observed major congenital malformations included: anhydramnios, cerebral ventriculomegaly, clubfoot (unresolved), Down syndrome, hydrops, hypospadias, patient ductus arteriosus, polydactyly (left foot), Potter syndrome, short stature, syndactyly (left foot, 1st and 2nd toes). Observed minor congenital malformations included: clubfoot (resolved), cryptorchidism (bilateral), dislocated hip, heart defect (patent foramen ovale), heart murmur (unresolved), hemangioma, hip dysplasia, hydrocele, inguinal hernia, head circumference -3 ≤ z-score <-2, persistent ductus arteriosus (resolved), plagiocephaly, restrictive ductus arteriosus, renal pyelectasis, sacral dimple, small perimembranous ventricular septal defect, stenosis of nasolacrimal duct, umbilical hernia. | Infants enrolled in HIV ZIP | Posted | Count of Participants | Participants | Infant birth, 3 months |
|
|
|
| Primary | Incidence of Other Adverse Outcomes Among Offspring of Women Co-infected With HIV and ZIKV, Women Infected With Either HIV or ZIKV Alone. | Other adverse outcomes included microcephaly, neonatal dealth, central nervous system (CNS) malformation, hydrops, and ocular abnormalities. Note there were no women with ZIKV infection in pregnancy. Microcephaly was defined as head circumference less than a z-score of -3 at birth or 3 month visit. Neonatal death was defined as death within 28 days of life. Observed CNS malformations included: cerebral ventriculomegaly. Ocular abnormalities included both structural and functional ophthalmologic abnormalities. | Infants enrolled in HIV ZIP | Posted | Count of Participants | Participants | Infant birth to 12 months |
|
|
|
| Primary | Weight Among Children With or Without in Utero Exposure to HIV and/or ZIKV | Weight as a measure of growth. Note there were no women with ZIKV infection in pregnancy. | Infants enrolled in HIV ZIP | Posted | Median | Inter-Quartile Range | kg | Infant Birth, 3 months, 6 months, 12 months |
|
|
|
| Primary | Length and Head Circumference Among Children With and Without in Utero Exposure to HIV and/or ZIKV | Length and head circumference as measures of growth. Note there were no women with ZIKV infection in pregnancy. | Infants enrolled in HIV ZIP | Posted | Median | Inter-Quartile Range | cm | Infant Birth, 3 months, 6 months, 12 months |
|
|
|
| Primary | Audiologic Function Among Children With or Without in Utero Exposure to HIV and/or ZIKV | Audiologic function as assessed by OAE test reported. Note there were no women with ZIKV infection in pregnancy. | Infants enrolled in HIV ZIP | Posted | Count of Participants | Participants | Within one month of infant birth, 3 months, 6 months, 12 months |
|
|
|
| Primary | Ophthalmologic Structure and Function Among Children With or Without in Utero Exposure to HIV and/or ZIKV | Ocular abnormalities included both structural and functional ophthalmologic abnormalities. Note there were no women with ZIKV infection in pregnancy. | Infants enrolled in HIV ZIP | Posted | Count of Participants | Participants | Within one month of infant birth, 12 months; |
|
|
|
| Primary | Neurodevelopment Among Children With or Without in Utero Exposure to HIV and/or ZIKV | Infant neurodevelopment was assessed by either the Bayley III or Ages and Stages Questionnaires- 3rd Edition. Combined results reported. Note there were no women with ZIKV infection in pregnancy. | Infants enrolled in HIV ZIP | Posted | Count of Participants | Participants | Infant 3 months, 6 months, 12 months |
|
|
|
| 174 |
| 0 |
| 174 |
| 0 |
| 174 |
| EG001 | Women With ZIKV Only | Pregnant women with ZIKV only | 0 | 0 | 0 | 0 | 0 | 0 |
| EG002 | Women With HIV and ZIKV | Pregnant women with HIV and ZIKV | 0 | 0 | 0 | 0 | 0 | 0 |
| EG003 | Women Without HIV or ZIKV | Pregnant women without HIV or ZIKV | 0 | 26 | 0 | 26 | 0 | 26 |
| EG004 | Infants of Women With HIV Only | Infants of women with HIV infection during pregnancy | 2 | 170 | 0 | 170 | 0 | 170 |
| EG005 | Infants of Women With ZIKV Only | Infants of women with ZIKV infection during pregnancy | 0 | 0 | 0 | 0 | 0 | 0 |
| EG006 | Infants of Women With HIV and ZIKV | Infants of women with HIV and ZIKV infection during pregnancy | 0 | 0 | 0 | 0 | 0 | 0 |
| EG007 | Infants of Women Without HIV or ZIKV | Infants of women without HIV or ZIKV infection during pregnancy | 0 | 25 | 0 | 25 | 0 | 25 |
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018177 | Flavivirus Infections |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| VL <400 copies/mL |
|
| VL <1000 copies/mL |
|
| Preterm delivery |
|
| CNS malformations |
|
| Hydrops |
|
| Ocular abnormalities |
|
| Weight at 6 months |
|
| Weight at 12 months |
|
| Length at 6 months |
|
| Length at 12 months |
|
| Head circumference at birth |
|
| Head circumference at 3 months |
|
| Head circumference at 6 months |
|
| Head circumference at 12 months |
|
| Test result not available |
|
| Right ear (3 months) |
|
| Right ear (6 months) |
|
| Right ear (12 months) |
|
| Left ear (Birth) |
|
| Left ear (3 months) |
|
| Left ear (6 months) |
|
| Left ear (12 months) |
|
| Missing |
|
| Failed screening test at 6 months |
|
| Failed screening test at 12 months |
|